Effects of acidic non-steroidal anti-inflammatory drugs on human cytochrome P450 4A11 activity: Roles of carboxylic acid and a sulfur atom in potent inhibition by sulindac sulfide

被引:1
作者
Itoh, Hisataka [1 ,2 ]
Yamashita, Naho [3 ]
Kamijo, Shinobu [2 ]
Masuda, Kazufumi [4 ]
Kato, Hisato [4 ]
Yamaori, Satoshi [1 ,2 ,5 ]
机构
[1] Shinshu Univ Hosp, Dept Pharm, 3-1-1 Asahi, Matsumoto, Nagano 3908621, Japan
[2] Shinshu Univ, Grad Sch Med, Dept Biochem Pharmacol & Toxicol, 3-1-1 Asahi, Matsumoto, Nagano 3908621, Japan
[3] Shinshu Univ, Sch Med, 3-1-1 Asahi, Matsumoto, Nagano 3908621, Japan
[4] Shujitsu Univ, Grad Sch Clin Pharm, Dept Phys Chem, 1-6-1 Nishigawara,Naka ku, Okayama 7038516, Japan
[5] Tokyo Univ Pharm & Life Sci, Sch Pharm, Dept Drug Metab & Mol Toxicol, 1432-1 Horinouchi, Hachioji, Tokyo 1920392, Japan
关键词
Non-steroidal anti-inflammatory drugs; Sulindac sulfide; Inhibition; Docking simulation; OMEGA-HYDROXYLASE; 20-HYDROXYEICOSATETRAENOIC ACID; HUMAN LIVER; ARACHIDONIC-ACID; HUMAN KIDNEY; CYP4A11; METABOLISM; EXPRESSION; ENZYMES; IDENTIFICATION;
D O I
10.1016/j.cbi.2023.110644
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Cytochrome P450 4A11 (CYP4A11) has many endogenous and exogenous compounds containing a carboxyl group in their structure as substrates. If drugs with this characteristic potently attenuate the catalytic function of CYP4A11, drug-drug interactions may occur. Acidic non-steroidal anti-inflammatory drugs (NSAIDs) possess a carboxylic acid in their structure. However, it remains unclear whether these drugs inhibit CYP4A11 activity. The present study examined the inhibitory effects of acidic NSAIDs on CYP4A11 activity using human liver microsomes (HLMs) and recombinant CYP4A11. Sulindac sulfide, ibuprofen, and flurbiprofen effectively decreased the luciferin-4A O-demethylase activity of HLMs and recombinant CYP4A11 (inhibition rates of 30-96% at an inhibitor concentration of 100 & mu;M), while salicylic acid, aspirin, diclofenac, mefenamic acid, indomethacin, etodolac, ketoprofen, loxoprofen, S-naproxen, pranoprofen, zaltoprofen, and oxaprozin exhibited weaker inhibitory activity (inhibition rates up to 23%). Among the drugs tested, sulindac sulfide was the most potent inhibitor of CYP4A11 activity. A kinetic analysis of the inhibition of CYP4A11 by sulindac sulfide revealed mixed-type inhibition for HLMs (Ki = 3.38 & mu;M) and recombinant CYP4A11 (Ki = 4.19 & mu;M). Sulindac sulfide is a pharmacologically active metabolite of sulindac (sulfoxide form), which is also oxidized to sulindac sulfone. To elucidate the role of a sulfur atom of sulindac sulfide in the inhibition of CYP4A11, the inhibitory effects of sulindac sulfide and its oxidized forms on CYP4A11 activity were examined. The potency of inhibition against HLMs was greater in the order of sulindac sulfide, sulindac, and sulindac sulfone; IC50 values were 6.16, 52.7, and 71.6 & mu;M, respectively. The present results indicate that sulindac sulfide is a potent inhibitor of CYP4A11. These results and the molecular modeling of CYP4A11 with sulindac sulfide and its oxidized forms suggest that a sulfur atom of sulindac sulfide as well as its carboxylic acid play important roles in the inhibition of CYP4A11.
引用
收藏
页数:9
相关论文
共 31 条
  • [1] Cytochrome P450 4A and 2E1 expression in human kidney microsomes
    Amet, Y
    Berthou, F
    Fournier, G
    Dreano, Y
    Bardou, L
    Cledes, J
    Menez, JF
    [J]. BIOCHEMICAL PHARMACOLOGY, 1997, 53 (06) : 765 - 771
  • [2] Effects of steric bulk and conformational rigidity on fatty acid omega hydroxylation by a cytochrome P450 4A1 fusion protein
    Bambal, RB
    Hanzlik, RP
    [J]. ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1996, 334 (01) : 59 - 66
  • [3] Studies on the Metabolism and Biological Activity of the Epimers of Sulindac
    Brunell, David
    Sagher, Daphna
    Kesaraju, Shailaja
    Brot, Nathan
    Weissbach, Herbert
    [J]. DRUG METABOLISM AND DISPOSITION, 2011, 39 (06) : 1014 - 1021
  • [4] DUGGAN DE, 1977, CLIN PHARMACOL THER, V21, P326
  • [5] Edson KZ, 2013, CURR TOP MED CHEM, V13, P1429
  • [6] The Central Role of Cytochrome P450 in Xenobiotic Metabolism-A Brief Review on a Fascinating Enzyme Family
    Esteves, Francisco
    Rueff, Jose
    Kranendonk, Michel
    [J]. JOURNAL OF XENOBIOTICS, 2021, 11 (03) : 94 - 114
  • [7] Analysis of the Human Tissue-specific Expression by Genome-wide Integration of Transcriptomics and Antibody-based Proteomics
    Fagerberg, Linn
    Hallstrom, Bjorn M.
    Oksvold, Per
    Kampf, Caroline
    Djureinovic, Dijana
    Odeberg, Jacob
    Habuka, Masato
    Tahmasebpoor, Simin
    Danielsson, Angelika
    Edlund, Karolina
    Asplund, Anna
    Sjostedt, Evelina
    Lundberg, Emma
    Szigyarto, Cristina Al-Khalili
    Skogs, Marie
    Takanen, Jenny Ottosson
    Berling, Holger
    Tegel, Hanna
    Mulder, Jan
    Nilsson, Peter
    Schwenk, Jochen M.
    Lindskog, Cecilia
    Danielsson, Frida
    Mardinoglu, Adil
    Sivertsson, Asa
    von Feilitzen, Kalle
    Forsberg, Mattias
    Zwahlen, Martin
    Olsson, IngMarie
    Navani, Sanjay
    Huss, Mikael
    Nielsen, Jens
    Ponten, Fredrik
    Uhlen, Mathias
    [J]. MOLECULAR & CELLULAR PROTEOMICS, 2014, 13 (02) : 397 - 406
  • [8] Functional variant of CYP4A11 20-hydroxyeicosatetraenoic acid synthase is associated with essential hypertension
    Gainer, JV
    Bellamine, A
    Dawson, EP
    Womble, KE
    Grant, SW
    Wang, YR
    Cupples, LA
    Guo, CY
    Demissie, S
    O'Donnell, CJ
    Brown, NJ
    Waterman, MR
    Capdevila, JH
    [J]. CIRCULATION, 2005, 111 (01) : 63 - 69
  • [9] Stereoselective sulfoxidation of sulindac sulfide by flavin-containing monooxygenases - Comparison of human liver and kidney microsomes and mammalian enzymes
    Hamman, MA
    Haehner-Daniels, BD
    Wrighton, SA
    Rettie, AE
    Hall, SD
    [J]. BIOCHEMICAL PHARMACOLOGY, 2000, 60 (01) : 7 - 17
  • [10] Methionine Sulfoxide Reductase A in Human and Mouse Tissues is Responsible for Sulindac Activation, Making a Larger Contribution than the Gut Microbiota
    Hirosawa, Keiya
    Fukami, Tatsuki
    Nagaoka, Mai
    Nakano, Masataka
    Nakajima, Miki
    [J]. DRUG METABOLISM AND DISPOSITION, 2022, 50 (05) : 725 - 733